质子泵抑制剂和化疗药物的协同效应

质子泵抑制剂（PPIs），H+/K+-ATPase抑制剂，是治疗胃食管反流征和消化性溃疡的最常用药物，它们很安全，而且耐受性好。由于PPIs经常被用于癌症患者，研究PPIs和抗癌药物之间的相互作用对于实现有效和安全的癌症化疗具有特别重要的意义。研究表明，PPIs不仅抑制胃壁细胞中H+/K+-ATPase，还抑制肿瘤细胞中表达的空泡型ATP酶（V-ATPase），以及与药代动力学和/或各种肾脏药物蓄积相关的有机阳离子转运蛋白2（OCT2），对化疗有减毒和增效作用。本文总结了PPIs对于化疗安全性和有效性的影响，为质子泵抑制剂更广的临床研究提供参考。

Synergistic Effects of Proton Pump Inhibitors and Chemotherapy Drugs

Proton pump inhibitors (PPIs), H+/K+-ATPase inhibitors, are the most commonly prescribed drugs for the treatment of gastroesophageal reflux and peptic ulcer diseases, and they are highly safe and tolerable. Since PPIs are frequently used in cancer patients, studies investigating interactions between PPIs and anticancer agents are of particular importance to achieving effective and safe cancer chemotherapy. Several studies have revealed that PPIs can inhibit the vacuolar H+-ATPase (V-ATPase) overexpressed in tumor cells, as well as the renal basolateral organic cation transporter 2 (OCT2) associated with pharmacokinetics and/or renal accumulation of various drugs. It can reduce toxicity and increase efficiency of chemotherapy. In this review, we summarize the current knowledge regarding the impact of PPIs on the efficacy and safety of cancer chemotherapeutics, to provide references for further clinical study of proton pump inhibitors.